From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
This article was originally published in PharmAsia News
Executive Summary
In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services